Jean-Didier Rain
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jean-Didier Rain.
Journal of Clinical Oncology | 2011
Jean-Jacques Kiladjian; Sylvie Chevret; Christine Dosquet; Christine Chomienne; Jean-Didier Rain
PURPOSE The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pipobroman as first-line therapy in 285 patients younger than age 65 years. PATIENTS AND METHODS The full methodology has been described previously. FPSG results were updated with a median follow-up of 16.3 years. Statistical analysis was performed by using competing risks on the intention-to-treat population and according to main treatment received. RESULTS Median survival was 17 years for the whole cohort, 20.3 years for the HU arm, and 15.4 years for the pipobroman arm (P = .008) and differed significantly from that in the general population. At 10, 15, and 20 years, cumulative incidence of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was 6.6%, 16.5%, and 24% in the HU arm and 13%, 34%, and 52% in the pipobroman arm (P = .004). Cumulative myelofibrosis incidence at 10, 15, and 20 years according to main treatment received was 15%, 24%, and 32% with HU versus 5%, 10%, and 21% with pipobroman (P = .02). CONCLUSION Data from this unique randomized trial comparing HU with another cytoreductive drug in PV showed that (1) survival of patients with PV treated with conventional agents differed from survival in the general population, (2) evolution to AML/MDS is the first cause of death, (3) pipobroman is leukemogenic and is unsuitable for first-line therapy, and (4) incidence of evolution to AML/MDS with HU is higher than previously reported, although consideration should be given to the natural evolution of PV.
British Journal of Haematology | 1991
Y. Najean; V. Dufour; Jean-Didier Rain; M. E. Toubert
Summary The significance of the site of platelet sequestration in determining the indication for splenectomy in idiopathic thrombocytopenic purpura (ITP) is a controversial subject. However, most of the negative conclusions are based on 51chromium labelling of homologous platelets. We report here the results of an analysis of 222 cases in which the kinetic study of 111indium‐oxinate‐labelled autologous platelets was performed under homogeneous technical conditions. 103 of these patients subsequently underwent splenectomy.
Clinical Nuclear Medicine | 2001
Marie-Elisabeth Toubert; Catherine Michel; Fabien Metivier; M. Can Peker; Jean-Didier Rain
The authors describe a patient with follicular thyroid carcinoma who was receiving continuous ambulatory peritoneal dialysis to manage end-stage renal disease. To deliver radioiodine therapy to ablate thyroid remnants safely and under optimal conditions, the behavior of 37 MBq (1 mCi) I-131 was followed daily for 3 days. Blood activity and total body count decreased with a half-life of 100 hours (4.17 days). The daily iodide removal rate, estimated as a percentage of the total administrated activity, was low: 5.3% to 8.6% in peritoneal dialysate and 1.3% to 2.2% in urine. The thyroid uptake, measured using a probe, was 2.4% to 2.1% from day 1 to day 3 and 1.9% later at day 8. The volume of thyroid remnants was determined by ultrasonography to be 0.6 g. The patient received a reduced ablative I-131 dose of 814 MBq (22 mCi). Radiation emitted from the patient after I-131 therapy, monitored using a radiation monitor probe located at a distance of 1 meter, decreased with an effective half-life of 70 hours (2.9 days). The integration of the curve from t = 0 showed a level always less than 25 &mgr;Sv/hour as early as 24 hours after treatment. Because the iodine removal rate is continuous but low in a case of peritoneal dialysis, smaller therapeutic doses must be administered to deliver maximal radiation to residual thyroid tissue while minimizing excessive radiation exposure to patients, their families, and medical staff.
Blood | 2005
Corinne Haioun; Emmanuel Itti; Alain Rahmouni; Pauline Brice; Jean-Didier Rain; Karim Belhadj; Philippe Gaulard; Laurent Garderet; Eric Lepage; Felix Reyes; Michel Meignan
Blood | 1997
Yves Najean; Jean-Didier Rain
Blood | 2006
Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-José Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
Blood | 1997
Yves Najean; Jean-Didier Rain
Blood | 2007
Marie-Paule Wautier; Wassim El Nemer; Pierre Gane; Jean-Didier Rain; Jean-Pierre Cartron; Yves Colin; Caroline Le Van Kim; Jean-Luc Wautier
Seminars in Thrombosis and Hemostasis | 2006
Jean-Jacques Kiladjian; Jean-Didier Rain; Jean-François Bernard; Jean Briere; Christine Chomienne; Pierre Fenaux
Blood | 2000
Bruno Cassinat; Philippe Guardiola; Sylvie Chevret; Marie-Helene Schlageter; Marie-Elisabeth Toubert; Jean-Didier Rain; Eliane Gluckman